Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention - FC2024-001

Next Previous
Trial Profile

zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention - FC2024-001

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Alpelisib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary) ; Epirubicin (Primary) ; Epirubicin (Primary) ; Eribulin (Primary) ; Etoposide (Primary) ; Everolimus (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Gemcitabine (Primary) ; Mirvetuximab soravtansine (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary) ; Palbociclib (Primary) ; Pembrolizumab (Primary) ; Ribociclib (Primary) ; Sacituzumab govitecan (Primary) ; Talazoparib (Primary) ; Topotecan (Primary) ; Topotecan (Primary) ; Trastuzumab-deruxtecan (Primary) ; Vinorelbine (Primary) ; Vinorelbine (Primary)
  • Indications Breast cancer; HER2 negative breast cancer; Ovarian cancer
  • Focus Therapeutic Use

Most Recent Events

  • 17 Sep 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top